Neonatal chylothorax is a potentially fatal respiratory condition caused by a congenital or traumatic etiology. Conventional therapies, such as fasting, total parenteral nutrition, and intravenous octreotide, are generally successful in such cases; however, more invasive therapeutic measures, such as pleurodesis, should be considered in refractory cases. This case report presents two preterm infants with refractory chylothorax who were non-responsive to conventional treatment but were successfully managed using hypertonic glucose pleurodesis. The first case was that of a female infant born at 24+5 weeks of gestation (585 g) and diagnosed with postsurgical chylothorax at 68 days of life. Even after the initiation of fasting and intravenous octreotide administration, pleural drainage did not reduce. Therefore, the patient underwent three intermittent procedures of 50% glucose pleurodesis, which resulted in the resolution of the chylothorax and subsequent chest tube removal after 37 days. The second case was a female infant born at 34+6 weeks (3,040 g), who was diagnosed with congenital chylothorax immediately after birth. Fasting and intravenous octreotide failed to show any clinical effects; therefore, the patient underwent pleurodesis for 3 consecutive days. After the procedure, the amount of pleural drainage substantially decreased, and the chest tube was removed after 14 days. In both cases, a temporal relation between pleurodesis and chylothorax resolution was observed, suggesting that hypertonic glucose pleurodesis may be an effective and safe alternative for treating refractory chylothorax in preterm infants with minimal side effects. Further studies are needed to establish the optimal protocol for this procedure and to compare its efficacy with that of other pleurodesis agents.

Objective: This study aims to isolate and identify aerobic and anaerobic bacterial species in the feces of wild KWD. Methods: Fecal samples were collected from 55 wild KWD of varying age and sex.Aerobic bacteria were cultured at 37°C for 24–48 h under standard conditions, whereas anaerobic bacteria were cultured at 37°C for 48–72 h in an anaerobic environment. Bacterial identification was conducted using DNA extraction and polymerase chain reaction amplification targeting the 16S rRNA gene. Results: The predominant aerobic bacteria identified belonged to the Firmicutes (58.18%) and Proteobacteria (41.82%) phyla, with Escherichia coli (31.82%) and Bacillus cereus (31.82%) being the most common species. Among anaerobic bacteria, most belonged to the Firmicutes (71.03%), Proteobacteria (27.10%), and Fusobacteriota (1.87%) phyla, with Paraclostridium bifermentans (28.97%) and E. coli (22.43%) being the most prevalent species.Other frequently identified anaerobic species were Fusobacterium varium, Lactococcus garvieae, Terrisporobacter glycolicus, Enterococcus faecalis, and Clostridium sporogenes. Conclusions and Relevance: Our findings indicate a diverse microbial community in the feces of water deer, offering valuable insights into their gut microbiota and its potential implications for health and ecology.

Neonatal chylothorax is a potentially fatal respiratory condition caused by a congenital or traumatic etiology. Conventional therapies, such as fasting, total parenteral nutrition, and intravenous octreotide, are generally successful in such cases; however, more invasive therapeutic measures, such as pleurodesis, should be considered in refractory cases. This case report presents two preterm infants with refractory chylothorax who were non-responsive to conventional treatment but were successfully managed using hypertonic glucose pleurodesis. The first case was that of a female infant born at 24+5 weeks of gestation (585 g) and diagnosed with postsurgical chylothorax at 68 days of life. Even after the initiation of fasting and intravenous octreotide administration, pleural drainage did not reduce. Therefore, the patient underwent three intermittent procedures of 50% glucose pleurodesis, which resulted in the resolution of the chylothorax and subsequent chest tube removal after 37 days. The second case was a female infant born at 34+6 weeks (3,040 g), who was diagnosed with congenital chylothorax immediately after birth. Fasting and intravenous octreotide failed to show any clinical effects; therefore, the patient underwent pleurodesis for 3 consecutive days. After the procedure, the amount of pleural drainage substantially decreased, and the chest tube was removed after 14 days. In both cases, a temporal relation between pleurodesis and chylothorax resolution was observed, suggesting that hypertonic glucose pleurodesis may be an effective and safe alternative for treating refractory chylothorax in preterm infants with minimal side effects. Further studies are needed to establish the optimal protocol for this procedure and to compare its efficacy with that of other pleurodesis agents.

Neonatal chylothorax is a potentially fatal respiratory condition caused by a congenital or traumatic etiology. Conventional therapies, such as fasting, total parenteral nutrition, and intravenous octreotide, are generally successful in such cases; however, more invasive therapeutic measures, such as pleurodesis, should be considered in refractory cases. This case report presents two preterm infants with refractory chylothorax who were non-responsive to conventional treatment but were successfully managed using hypertonic glucose pleurodesis. The first case was that of a female infant born at 24+5 weeks of gestation (585 g) and diagnosed with postsurgical chylothorax at 68 days of life. Even after the initiation of fasting and intravenous octreotide administration, pleural drainage did not reduce. Therefore, the patient underwent three intermittent procedures of 50% glucose pleurodesis, which resulted in the resolution of the chylothorax and subsequent chest tube removal after 37 days. The second case was a female infant born at 34+6 weeks (3,040 g), who was diagnosed with congenital chylothorax immediately after birth. Fasting and intravenous octreotide failed to show any clinical effects; therefore, the patient underwent pleurodesis for 3 consecutive days. After the procedure, the amount of pleural drainage substantially decreased, and the chest tube was removed after 14 days. In both cases, a temporal relation between pleurodesis and chylothorax resolution was observed, suggesting that hypertonic glucose pleurodesis may be an effective and safe alternative for treating refractory chylothorax in preterm infants with minimal side effects. Further studies are needed to establish the optimal protocol for this procedure and to compare its efficacy with that of other pleurodesis agents.

Objective: This study aims to isolate and identify aerobic and anaerobic bacterial species in the feces of wild KWD. Methods: Fecal samples were collected from 55 wild KWD of varying age and sex.Aerobic bacteria were cultured at 37°C for 24–48 h under standard conditions, whereas anaerobic bacteria were cultured at 37°C for 48–72 h in an anaerobic environment. Bacterial identification was conducted using DNA extraction and polymerase chain reaction amplification targeting the 16S rRNA gene. Results: The predominant aerobic bacteria identified belonged to the Firmicutes (58.18%) and Proteobacteria (41.82%) phyla, with Escherichia coli (31.82%) and Bacillus cereus (31.82%) being the most common species. Among anaerobic bacteria, most belonged to the Firmicutes (71.03%), Proteobacteria (27.10%), and Fusobacteriota (1.87%) phyla, with Paraclostridium bifermentans (28.97%) and E. coli (22.43%) being the most prevalent species.Other frequently identified anaerobic species were Fusobacterium varium, Lactococcus garvieae, Terrisporobacter glycolicus, Enterococcus faecalis, and Clostridium sporogenes. Conclusions and Relevance: Our findings indicate a diverse microbial community in the feces of water deer, offering valuable insights into their gut microbiota and its potential implications for health and ecology.

Objective: This study aims to isolate and identify aerobic and anaerobic bacterial species in the feces of wild KWD. Methods: Fecal samples were collected from 55 wild KWD of varying age and sex.Aerobic bacteria were cultured at 37°C for 24–48 h under standard conditions, whereas anaerobic bacteria were cultured at 37°C for 48–72 h in an anaerobic environment. Bacterial identification was conducted using DNA extraction and polymerase chain reaction amplification targeting the 16S rRNA gene. Results: The predominant aerobic bacteria identified belonged to the Firmicutes (58.18%) and Proteobacteria (41.82%) phyla, with Escherichia coli (31.82%) and Bacillus cereus (31.82%) being the most common species. Among anaerobic bacteria, most belonged to the Firmicutes (71.03%), Proteobacteria (27.10%), and Fusobacteriota (1.87%) phyla, with Paraclostridium bifermentans (28.97%) and E. coli (22.43%) being the most prevalent species.Other frequently identified anaerobic species were Fusobacterium varium, Lactococcus garvieae, Terrisporobacter glycolicus, Enterococcus faecalis, and Clostridium sporogenes. Conclusions and Relevance: Our findings indicate a diverse microbial community in the feces of water deer, offering valuable insights into their gut microbiota and its potential implications for health and ecology.

Neonatal chylothorax is a potentially fatal respiratory condition caused by a congenital or traumatic etiology. Conventional therapies, such as fasting, total parenteral nutrition, and intravenous octreotide, are generally successful in such cases; however, more invasive therapeutic measures, such as pleurodesis, should be considered in refractory cases. This case report presents two preterm infants with refractory chylothorax who were non-responsive to conventional treatment but were successfully managed using hypertonic glucose pleurodesis. The first case was that of a female infant born at 24+5 weeks of gestation (585 g) and diagnosed with postsurgical chylothorax at 68 days of life. Even after the initiation of fasting and intravenous octreotide administration, pleural drainage did not reduce. Therefore, the patient underwent three intermittent procedures of 50% glucose pleurodesis, which resulted in the resolution of the chylothorax and subsequent chest tube removal after 37 days. The second case was a female infant born at 34+6 weeks (3,040 g), who was diagnosed with congenital chylothorax immediately after birth. Fasting and intravenous octreotide failed to show any clinical effects; therefore, the patient underwent pleurodesis for 3 consecutive days. After the procedure, the amount of pleural drainage substantially decreased, and the chest tube was removed after 14 days. In both cases, a temporal relation between pleurodesis and chylothorax resolution was observed, suggesting that hypertonic glucose pleurodesis may be an effective and safe alternative for treating refractory chylothorax in preterm infants with minimal side effects. Further studies are needed to establish the optimal protocol for this procedure and to compare its efficacy with that of other pleurodesis agents.

Objective: This study aims to isolate and identify aerobic and anaerobic bacterial species in the feces of wild KWD. Methods: Fecal samples were collected from 55 wild KWD of varying age and sex.Aerobic bacteria were cultured at 37°C for 24–48 h under standard conditions, whereas anaerobic bacteria were cultured at 37°C for 48–72 h in an anaerobic environment. Bacterial identification was conducted using DNA extraction and polymerase chain reaction amplification targeting the 16S rRNA gene. Results: The predominant aerobic bacteria identified belonged to the Firmicutes (58.18%) and Proteobacteria (41.82%) phyla, with Escherichia coli (31.82%) and Bacillus cereus (31.82%) being the most common species. Among anaerobic bacteria, most belonged to the Firmicutes (71.03%), Proteobacteria (27.10%), and Fusobacteriota (1.87%) phyla, with Paraclostridium bifermentans (28.97%) and E. coli (22.43%) being the most prevalent species.Other frequently identified anaerobic species were Fusobacterium varium, Lactococcus garvieae, Terrisporobacter glycolicus, Enterococcus faecalis, and Clostridium sporogenes. Conclusions and Relevance: Our findings indicate a diverse microbial community in the feces of water deer, offering valuable insights into their gut microbiota and its potential implications for health and ecology.

Neonatal chylothorax is a potentially fatal respiratory condition caused by a congenital or traumatic etiology. Conventional therapies, such as fasting, total parenteral nutrition, and intravenous octreotide, are generally successful in such cases; however, more invasive therapeutic measures, such as pleurodesis, should be considered in refractory cases. This case report presents two preterm infants with refractory chylothorax who were non-responsive to conventional treatment but were successfully managed using hypertonic glucose pleurodesis. The first case was that of a female infant born at 24+5 weeks of gestation (585 g) and diagnosed with postsurgical chylothorax at 68 days of life. Even after the initiation of fasting and intravenous octreotide administration, pleural drainage did not reduce. Therefore, the patient underwent three intermittent procedures of 50% glucose pleurodesis, which resulted in the resolution of the chylothorax and subsequent chest tube removal after 37 days. The second case was a female infant born at 34+6 weeks (3,040 g), who was diagnosed with congenital chylothorax immediately after birth. Fasting and intravenous octreotide failed to show any clinical effects; therefore, the patient underwent pleurodesis for 3 consecutive days. After the procedure, the amount of pleural drainage substantially decreased, and the chest tube was removed after 14 days. In both cases, a temporal relation between pleurodesis and chylothorax resolution was observed, suggesting that hypertonic glucose pleurodesis may be an effective and safe alternative for treating refractory chylothorax in preterm infants with minimal side effects. Further studies are needed to establish the optimal protocol for this procedure and to compare its efficacy with that of other pleurodesis agents.

BACKGROUND: A drug-eluting stent (DES) is a highly beneficial medical device used to widen or unblock narrowed blood vessels. However, the drugs released by the implantation of DES may hinder the re-endothelialization process, increasing the risk of late thrombosis. We have developed a tacrolimus-eluting stent (TES) that as acts as a potent antiproliferative and immunosuppressive agent, enhancing endothelial regeneration. In addition, we assessed the safety and efficacy of TES through both in vitro and in vivo tests. METHODS: Tacrolimus and Poly(lactic-co-glycolic acid) (PLGA) were applied to the metal stent using electrospinning equipment. The surface morphology of the stent was examined before and after coating using a scanning electron microscope (SEM) and energy dispersive X-rays (EDX). The drug release test was conducted through high-performance liquid chromatography (HPLC). Cell proliferation and migration assays were performed using smooth muscle cells (SMC).The stent was then inserted into the porcine coronary artery and monitored for a duration of 4 weeks. RESULTS: SEM analysis confirmed that the coating surface was uniform. Furthermore, EDX analysis showed that the surface was coated with both polymer and drug components. The HPCL analysis of TCL at a wavelength of 215 nm revealed that the drug was continuously released over a period of 4 weeks. Smooth muscle cell migration was significantly decreased in the tacrolimus group (54.1% ± 11.90%) compared to the non-treated group (90.1% ± 4.86%). In animal experiments, the stenosis rate was significantly reduced in the TES group (29.6% ± 7.93%) compared to the bare metal stent group (41.3% ± 10.18%). Additionally, the fibrin score was found to be lower in the TES group compared to the group treated with a sirolimus-eluting stent (SES). CONCLUSION Similar to SES, TES reduces neointimal proliferation in a porcine coronary artery model, specifically decreasing the fibrins score. Therefore, tacrolimus could be considered a promising drug for reducing restenosis and thrombosis.